Neuropathological Alterations in Alzheimer Disease

Alberto Serrano-Pozo1, Matthew P. Frosch1,2, Eliezer Masliah3, and Bradley T. Hyman1

1Alzheimer Research Unit of the MassGeneral Institute for Neurodegenerative Disease, Department of Neurology of the Massachusetts General Hospital, and Harvard Medical School, Charlestown, Massachusetts 02129-4404
2C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, Massachusetts 02114
3Department of Neuroscience and Department of Pathology, University of California-San Diego School of Medicine, La Jolla, California 92093-0624

Correspondence: bhyman@partners.org

The neuropathological hallmarks of Alzheimer disease (AD) include “positive” lesions such as amyloid plaques and cerebral amyloid angiopathy, neurofibrillary tangles, and glial responses, and “negative” lesions such as neuronal and synaptic loss. Despite their inherently cross-sectional nature, postmortem studies have enabled the staging of the progression of both amyloid and tangle pathologies, and, consequently, the development of diagnostic criteria that are now used worldwide. In addition, clinicopathological correlation studies have been crucial to generate hypotheses about the pathophysiology of the disease, by establishing that there is a continuum between “normal” aging and AD dementia, and that the amyloid plaque build-up occurs primarily before the onset of cognitive deficits, while neurofibrillary tangles, neuron loss, and particularly synaptic loss, parallel the progression of cognitive decline. Importantly, these cross-sectional neuropathological data have been largely validated by longitudinal in vivo studies using modern imaging biomarkers such as amyloid PET and volumetric MRI.

The neuropathological changes of Alzheimer disease (AD) brain include both positive and negative features. Classical positive lesions consist of abundant amyloid plaques and neurofibrillary tangles, neuritopil threads, and dystrophic neurites containing hyperphosphorylated tau (see Box 1 for glossary) (Terry et al. 1994, Mandelkow and Mandelkow 1998, Trojanowski and Lee 2000; Iqbal and Grundke-Iqbal 2002; Crews and Masliah 2010), that are accompanied by astrogliosis (Beach et al. 1989; Itagaki et al. 1989), and microglial cell activation (Rogers et al. 1988; Itagaki et al. 1989; Masliah et al. 1991). Congophilic amloid angiopathy is a frequent concurrent feature. Unique lesions, found primarily in the hippocampal formation, include Hirano bodies and granulovacuolar degeneration. In addition to these positive lesions, characteristic losses of neurons, neuritopil, and synaptic elements are core negative features of AD (Scheff et al. 1990, 2006, 2007; DeKosky and Scheff 1990;
Each of these lesions has a characteristic distribution, with plaques found throughout the cortical mantle, and tangles primarily in limbic and association cortices (Arnold et al. 1991; Braak and Braak 1991; Thal et al. 2002). The hierarchical pattern of neurofibrillary degeneration among brain regions is so consistent that a staging scheme based on early lesions in the entorhinal/perirhinal cortex, then hippocampal Ammon subfields, then association cortex, and finally primary neocortex is well accepted as part of the 1997 NIA-Reagan diagnostic criteria (NIA-RI Consensus 1997). Neuronal loss and synapse loss largely parallel tangle formation, although whether tangles are causative of neuronal loss or synaptic loss remains uncertain (Gómez-Isla et al. 1997; Iqbal and Grundke-Iqbal 2002; Bussière et al. 2003; Hof et al. 2003; Yoshiyama et al. 2007; Spires-Jones et al. 2008; de Calignon et al. 2009, 2010; Kimura et al. 2010).

**BOX 1. Glossary**

**Amyloid plaques:** extracellular deposits of amyloid β abundant in the cortex of AD patients. Amyloid plaques are commonly classified in diffuse and dense-core based on their morphology and positive or negative staining with Thioflavin-S or Congo Red.

**Dense-core plaques:** fibrillar amyloid deposits with compact core that stains with Thioflavin-S and Congo Red. Dense-core plaques are typically surrounded by dystrophic neurites (neuritic plaques), reactive astrocytes and activated microglial cells, and associated with synaptic loss. A semi-quantitative score of neuritic plaques is used for the pathological diagnosis of AD because their presence is generally associated with the presence of cognitive impairment.

**Diffuse plaques:** amorphous amyloid deposits with ill-defined contours that are Congo Red and Thioflavin S negative. Diffuse plaques are usually nonneuritic and not associated with glial responses or synaptic loss. This plaque type is not considered for the pathological diagnosis of AD because it is a relatively common finding in the brain of cognitively intact elderly people.

**Cerebral amyloid angiopathy (CAA):** deposits of amyloid β in the tunica media of leptomeningeal arteries and cortical capillaries, small arterioles and medium-size arteries, particularly in posterior areas of the brain. Some degree of CAA, usually mild, is present in ≈80% of AD patients. If severe, CAA can weaken the vessel wall and cause life-threatening lobar hemorrhages.

**Amyloid β:** a 40 or 42 amino acid peptide derived from amyloid precursor protein (APP) after its sequential cleavage by β- and γ-secretases. Its physiological role is likely related to the modulation of synaptic activity although still controversial. In AD Aβ accumulates forming intermediate soluble oligomers that are synaptotoxic as well as insoluble β-sheet pleated amyloid fibrils that are the main constituent of dense-core plaques (mainly Aβ42) and cerebral amyloid angiopathy (primarily Aβ40).

**Neurofibrillary tangles (NFTs):** intraneuronal aggregates of hyperphosphorylated and misfolded tau that become extraneuronal (“ghost” tangles) when tangle-bearing neurons die. NFTs have a stereotypical spatiotemporal progression that correlates with the severity of the cognitive decline. In fact, a topographic staging of NFTs (Braak and Braak 1991) is used for the pathological diagnosis of AD.

**Neuropil threads:** axonal and dendritic segments containing aggregated and hyperphosphorylated tau that invariably accompany neurofibrillary tangles in AD.

**Tau:** a microtubule-associated protein normally located to the axon, where it physiologically facilitates the axonal transport by binding and stabilizing the microtubules. In AD, tau is translocated to the somatodendritic compartment and undergoes hyperphosphorylation, misfolding, and aggregation, giving rise to neurofibrillary tangles and neuropil threads.
Although all these neuropathological characteristics are useful diagnostic markers, the cognitive impairment in patients with AD is closely associated with the progressive degeneration of the limbic system (Arnold et al. 1991; Klucken et al. 2003), neocortical regions (Terry et al. 1981), and the basal forebrain (Teipel et al. 2005). This neurodegenerative process is characterized by early damage to the synapses (Masliah and Terry 1993, 1994; Masliah 2000; Crews and Masliah 2010) with retrograde degeneration of the axons and eventual atrophy of the dendritic tree (Coleman and Perry 2002; Higuchi et al. 2002; Grutzendler et al. 2007; Perlson et al. 2010) and perikaryon (Hyman et al. 1986; Lippa et al. 1992). Indeed, the loss of synapses in the neocortex and limbic system is the best correlate of the cognitive impairment in patients with AD (DeKosky and Scheff 1990; Terry et al. 1991; DeKosky et al. 1996).

In addition to the lesions detected by classical histopathological stains, including silver stains for tangles and plaques or immunostaining and quantitative analysis (or quantitative EM) for synaptic alterations, several lines of investigation now support the view that increased levels of soluble amyloid-β (Aβ) oligomers, might lead to synaptic damage and neurodegeneration (Lambert et al. 1998; Klein et al. 2001; Klein 2002; Walsh et al. 2002; Walsh and Selkoe 2004; Glabe 2005; Lesne et al. 2006; Townsend et al. 2006; Lacor et al. 2007). In experimental models, it has been shown that transsynaptic delivery of Aβ, for example from the entorhinal cortex to the molecular layer of the dentate gyrus, promotes neurodegeneration characterized by synapse loss (Harris et al. 2010a) and alterations to calbindin-positive neurons (Palop et al. 2003). This is accompanied by circuitry dysfunction and aberrant innervation of the hippocampus by NPY-positive fibers among others (Harris et al. 2010b; Palop et al. 2011). The Aβ oligomers secreted by cultured neurons inhibit long-term potentiation (LTP), damage spines and interfere with activity-regulated cytoskeleton associated protein (Arc) distribution (Klein et al. 2001; Walsh and Selkoe 2004; Townsend et al. 2006; Selkoe 2008). Together, these studies indicate that Aβ oligomers ranging in size from 2 to 12 subunits might be responsible for the synaptic damage and memory deficits in AD (Lacor et al. 2007). Similar neurotoxic Aβ oligomers found in vitro and in APP transgenic models have been also identified in the CSF (Klyubin et al. 2008) and in the brains of patients with AD (Shankar et al. 2008; McDonald et al. 2010; Pham et al. 2010). These studies have shown that Aβ oligomers progressively accumulate in the brains of AD patients, although their relationship to the severity of the cognitive impairment remains uncertain.

In summary, in recent years, the concept of neurodegeneration in AD has been expanded from the idea of general neuronal loss and astrogliosis to include earlier alterations such as synaptic and dendritic injury and disturbances in the process of adult neurogenesis (Jin et al. 2004; Li et al. 2008; Crews et al. 2010), circuitry dysfunction, and aberrant innervation. All of these factors are important targets to consider when developing neuroprotective treatments for AD.

MACROSCOPIC FEATURES

Although the gross visual examination of the AD brain is not diagnostic, a typical symmetric pattern of cortical atrophy predominantly affecting the medial temporal lobes and relatively sparing the primary motor, sensory, and visual cortices, is considered strongly suggestive of AD being the condition underlying the patient’s dementia. As a result of this pattern of cortical thinning, the lateral ventricles, particularly their temporal horns, can appear prominently dilated (ex vacuo hydrocephalus). This pattern is stereotypic and can be recognized early in the clinical course of the disease by MRI scan (Dickerson et al. 2009, 2011). Cerebrovascular disease, usually in the form of small vessel occlusive disease caused by chronic hypertension and other vascular risk factors, is a condition that frequently accompanies aging in general and also AD in particular. Thus, it is relatively common to find some cortical
microinfarcts, lacunar infarcts in the basal ganglia, and demyelination of the periventricular white matter. The presence of cortical petechial microbleeds or even evident lobar hemorrhages, particularly in the posterior parietal and occipital lobes, should lead to the suspicion of a concurrent severe cerebral amyloid angiopathy. Unless there is a concomitant Parkinson’s disease or dementia with Lewy bodies, the substantia nigra shows a normal coloration; in contrast, the locus coeruleus is affected in the early stages of AD (Braak and Del Tredici 2011).

**MICROSCOPIC FEATURES**

**Neurofibrillary Tangles**

**Composition**

The neurofibrillary tangles (NFTs) were first described by Alois Alzheimer in his original autopsy case report as intraneuronal filamentous inclusions within the perikaryal region of pyramidal neurons. Ultrastructural studies on AD brain specimens revealed that NFTs are primarily made of paired helical filaments (PHFs), that is, fibrils of ≈10 nm in diameter that form pairs with a helical tridimensional conformation at a regular periodicity of ≈65 nm (Kidd 1963, 1964; Wisniewski et al. 1976). A small proportion of fibrils within the NFTs do not form pairs, but give the appearance of straight filaments without the periodicity of PHFs (Crowther 1991). Occasional hybrid filaments, with a sharp transition between a paired helical segment and a straight segment, have also been described within NFTs (Crowther 1991). Recently, modern high-resolution molecular microscopy techniques have revealed the presence of twisted ribbon-like assemblies of tau fibrils in vitro, thus challenging the PHF concept (Wegmann et al. 2010). Regardless of the morphology of their structural units, the major constituent of NFTs was found to be the microtubule-associated protein tau, which is aberrantly misfolded and abnormally hyperphosphorylated. Invariably accompanying NFTs are the neuropil threads, which are thought to result from the breakdown of dendrites and axons of the tangle-bearing neurons.

**Morphological Characteristics**

The NFTs are argyrophilic and can be shown by silver impregnation methods such as the Gallyas technique (Braak and Braak 1991). An alternative method to examine NFTs is their staining with fluorescent dyes such as Thioflavin-S, which recognize the β-sheet pleated structure of the paired helical filaments (Arnold et al. 1991), or by immunostaining with anti-tau antibodies (Fig. 1). Three morphological stages have been distinguished: (1) Pre-NFTs or diffuse NFTs are defined by a diffuse, sometimes punctate, tau staining within the cytoplasm of otherwise normal-looking neurons, with well-preserved dendrites and a centered nucleus; (2) Mature or fibrillar intraneuronal NFTs (iNFTs) consist of cytoplasmic filamentous aggregates of tau that displace the nucleus toward the periphery of the soma and often extend to distorted-appearing dendrites and to the proximal segment of the axon; (3) extraneuronal “ghost” NFTs (eNFTs) result from the death of the tangle-bearing neurons and are identifiable by the absence of nucleus and stainable cytoplasm (Su et al. 1993; Braak et al. 1994; Augustinack et al. 2002). Both silver and Thioflavin-S stains, as well as some phosphotau antibodies such as AT8 and PHF1, preferentially identify the iNFTs and the eNFTs (Braak et al. 1994; Augustinack et al. 2002). By contrast, other phosphoepitopes (e.g., pThr153, pSer262, pThr231) and a certain conformational epitope recognized by the antibodies MC1 and Alz50 also recognize pre-NFTs, suggesting that the misfolding of the tau molecule and its phosphorylation in certain sites represent an early step prior to tau aggregation (Carmel et al. 1996; Weaver et al. 2000; Augustinack et al. 2002). Interestingly, the immunoreactivity for a caspase-cleaved form of tau with a faster rate of fibrillization than the full length molecule in vitro colocalize with Alz50 immunoreactivity in pre-NFTs, suggesting that the caspase-mediated cleavage of the carboxy-terminal region of the tau molecule is
also a necessary step prior to further aggregation (Guillozet-Bongaarts et al. 2005).

**Topographical Distribution**

The spatiotemporal pattern of progression of NFTs (and neuropil threads in parallel) is rather stereotypical and predictable (Arnold et al. 1991; Braak and Braak 1991; Braak et al. 2006). Briefly, the neurofibrillary degeneration starts in the allocortex of the medial temporal lobe (entorhinal cortex and hippocampus) and spreads to the associative isocortex, relatively sparing the primary sensory, motor, and visual areas. In their clinicopathological study, Braak and Braak distinguished six stages that can be summarized in three: entorhinal, limbic, and isocortical (Fig. 2). The first NFTs consistently appear in the transentorhinal (perirhinal) region (stage I) along with the entorhinal cortex proper, followed by the CA1 region of the hippocampus (stage II). Next, NFTs develop and accumulate in limbic structures such as the subiculum of the hippocampal formation (stage III) and the amygdala, thalamus, and claustrum (stage IV). Finally, NFTs spread to all isocortical areas (isocortical stage), with the associative areas being affected prior and more severely (stage V) than the primary sensory, motor, and visual areas (stage VI). A severe involvement of striatum and substantia nigra can occur during the late isocortical stage. Of note, this neurofibrillary degeneration follows a laminar pattern affecting preferentially the stellate neurons of layer II, the superficial portion of layer III, and the large multipolar neurons of layers III and V within the isocortical areas (Hyman et al. 1984; Arnold et al. 1991; Braak and Braak 1991).

**Clinicopathological Correlations**

Multiple clinicopathological studies from different groups have established that the amount and distribution of NFTs correlate with the severity and the duration of dementia (Arrigada et al. 1992a; Bierer et al. 1995; Gómez-Isla et al. 1991; Braak and Braak 1991).

![Figure 1. Photomicrographs of the core pathological lesions observed in Alzheimer and Lewy body diseases.](image-url)
Moreover, the selective rather than widespread topographical distribution of NFTs described above matches with the hierarchical neuropsychological profile typical of the AD-type dementia syndrome. The prominent initial impairment of episodic memory characteristic of AD is explained by the isolation of the medial temporal lobe structures from the association isocortex and the subcortical nuclei because of the ongoing massive neurofibrillary degeneration. Next, the involvement of multi-modal high-order association isocortical areas accounts for the progressive impairment of additional cognitive domains, including executive dysfunction (prefrontal cortex), apraxias (parietal cortex), visuospatial navigation deficits (occipitotemporal cortex), visuoperceptive deficits (occipitoparietal cortex), and semantic memory (anterior temporal cortex), giving rise to the full-blown dementia syndrome. By contrast, the late involvement of primary motor, sensory, and primary visual functions (Hyman et al. 1984; Arnold et al. 1991; Braak and Braak 1991). However, as discussed below, whether NFT formation is a necessary precursor of the neuronal death in AD or represents a protective response of damaged neurons (and thus more of a surrogate marker of the ongoing pathological process) is still controversial.

### Amyloid Plaques

#### Composition

The senile plaques described by Alois Alzheimer in his original case report result from the abnormal extracellular accumulation and deposition of the amyloid-β peptide (Aβ) with 40 or 42 amino acids (Aβ40 and Aβ42), two normal byproducts of the metabolism of the amyloid precursor protein (APP) after its sequential cleavage by the enzymes β- and γ-secretases in neurons. Because of its higher rate of fibrillation and insolubility, Aβ42 is more abundant than Aβ40 within the plaques.
Morphological Characteristics

Attempts to understand the evolution of the amyloid plaque after its formation based on morphological criteria gave rise to a number of terms, including “primitive,” “classical,” and “burn-out” plaques. However, a more practical and widely used morphological classification distinguishes only two types of amyloid plaques—diffuse versus dense-core plaques—based on their staining with dyes specific for the β-sheet pleated sheet conformation such as Congo Red and Thioflavin-S. This simpler categorization is relevant to the disease because, unlike diffuse Thioflavin-S negative plaques, Thioflavin-S positive dense-core plaques are associated with deleterious effects on the surrounding neuropil including increased neurite curvature and dystrophic neurites, synaptic loss, neuron loss, and recruitment and activation of both astrocytes and microglial cells (Itagaki et al. 1989; Masliah et al. 1990, 1994; Pike et al. 1995; Knowles et al. 1999; Urbanc et al. 2002; Vehmas et al. 2003). Indeed, diffuse amyloid plaques are commonly present in the brains of cognitively intact elderly people, whereas dense-core plaques, particularly those with neuritic dystrophies, are most often found in patients with AD dementia. However, the pathological boundaries between normal aging and AD dementia are not clear-cut and, as we will further discuss below, many cognitively normal elderly people have substantial amyloid burden in their brains.

Electron microscopy studies revealed that the ultrastructure of dense-core plaques is comprised of a central mass of extracellular filaments that radially extend toward the periphery, where they are intermingled with neuronal, astrocytic, and microglial processes. These neuronal processes, known as dystrophic neurites, are often paired helical filaments, as well as abundant abnormal mitochondria and dense bodies of probable mitochondrial and lysosomal origin (Kidd 1964; Hirai et al. 2001; Fiala et al. 2007). Plaque-associated neuritic dystrophies represent the most notorious evidence of Aβ-induced neurotoxicity and feature many of the pathophysiological processes downstream Aβ. Their origin can be axonal or dendritic and their morphology can be either elongated and distorted or bulbous (Su et al. 1993). They can be argyrophilic (Fig. 1C) and Thioflavin-S positive because of the aggregation of β-sheet pleated tau fibrils, which can also be shown with many phosphotau and conformation-specific tau antibodies (Su et al. 1993, 1994, 1996). Interestingly, dystrophic neurites can also be immunoreactive for APP (Cras et al. 1991; Su et al. 1998). Cytoskeletal abnormalities in dystrophic neurites explain their immunoreactivity for neurofilament proteins (Su et al. 1996, 1998; Dickson et al. 1999; Woodhouse et al. 2006a; Pérez-Gracia et al. 2008). Moreover, some axonal dystrophic neurites contain either cholinergic, glutamatergic, or gabaergic markers, suggesting a plaque-induced aberrant sprouting (Benzing et al. 1993; Ferrer et al. 1993; Masliah et al. 2003; Bell et al. 2007). Finally, dystrophic neurites can be displayed with immunohistochemical studies for ubiquitin and lysosomal proteins, indicating that there is a compensatory attempt to degrade and clear the abnormal accumulation of proteins and organelles (Dickson et al. 1990; Barrachina et al. 2006). A less-evident expression of the plaque-induced neuritic changes is the increase in the curvature of neurites located in the proximity of dense-core plaques (Knowles et al. 1999).

Topographic Distribution

Unlike NFTs, amyloid plaques accumulate mainly in the isocortex. Although the spatio-temporal pattern of progression of amyloid deposition is far less predictable than that of NFTs, in general the allocortex (including entorhinal cortex and hippocampal formation), the basal ganglia, relevant nuclei of the
brainstem, and the cerebellum, are involved to a lesser extent and later than the associative isocortex. The dissociation between amyloid and NFT burdens in the medial temporal lobe is particularly noticeable. Among the isocortical areas, likewise NFTs, primary sensory, motor, and visual areas tend to be less affected as compared to association multimodal areas. (Arnold et al. 1991; Braak and Braak 1991). Despite this poorer predictability of the progression of amyloid deposition, two staging systems have been proposed. Braak and Braak distinguished three stages: (1) Stage A, with amyloid deposits mainly found in the basal portions of the frontal, temporal, and occipital lobes; (2) Stage B, with all isocortical association areas affected while the hippocampal formation is only mildly involved, and the primary sensory, motor, and visual cortices are devoid of amyloid; and (3) Stage C, characterized by the deposition of amyloid in these primary isocortical areas and, in some cases, the appearance of amyloid deposits in the molecular layer of the cerebellum (Braak and Braak 1991). Thal et al. proposed a descendent progression of amyloid deposition in five stages: (1) Stage 1 or isocortical; (2) Stage 2, with additional allocortical deposits (entorhinal cortex, hippocampal formation, amygdala, insular, and cingulated cortices); (3) Stage 3, with additional involvement of subcortical nuclei including striatum, basal forebrain cholinergic nuclei, thalamus and hypothalamus, and white matter; (4) Stage 4, characterized by the involvement of brainstem structures, including red nucleus, substantia nigra, reticular formation of the medulla oblongata, superior and inferior colliculi; and (5) Stage 5, with additional amyloid deposits in the pons (reticular formation, raphe nuclei, locus ceruleus) and the molecular layer of the cerebellum (Thal et al. 2002). These five Thal stages can be summarized in three: stage 1 or isocortical; stage 2, allocortical or limbic, and stage 3 or subcortical (Fig. 3).

Amyloid deposits usually involve the six layers of the isocortex, although layers I and VI are usually relatively more spared than layers II-V (Arnold et al. 1991; Braak and Braak 1991). However, in advanced cases it is frequent to observe band-like diffuse amyloid deposits in the subpial surface of the cortex and even a few amyloid deposits in the white matter close to its transition with the cortical layer VI.

Figure 3. Spatiotemporal pattern of amyloid plaque deposition according to Thal et al. (2002). Coronal (A), axial (B), and sagittal (C) views of the brain. The five Thal stages of amyloid deposition are here summarized in three stages. Amyloid deposits accumulate first in isocortical areas (stage 1 or isocortical, in red), followed by limbic and allocortical structures (stage 2 or limbic, in orange), and in a later stage, by subcortical structures including basal ganglia, selected nuclei in diencephalon and brainstem, and the cerebellar cortex (stage 3 or subcortical, in yellow). Amyg = Amygdala; EC = Entorhinal cortex; Hipp = Hippocampus; Cg = Cingulate cortex; Cd = Caudate nucleus; Put = Putamen; Gpe = Globus pallidus externus; Gpi = Globus pallidus internus; Cl = Claustrum; Ins = Insular cortex; Die = Diencephalon; Mid = Midbrain; Med = Medulla oblongata; Cblm = Cerebellum.
Clinicopathological Correlations
Clinicopathological studies have established that the amyloid burden (either total amyloid plaques, dense-core plaques or only neuritic plaques) does not correlate with the severity or the duration of dementia (Arriagada et al. 1992a, Hyman et al. 1993; Bierer et al. 1995; Gómez-Isla et al. 1997; Giannakopoulos et al. 2003; Ingelsson et al. 2004). Indeed, in a region of early amyloid deposition such as the temporal associative isocortex, the amyloid burden reaches a plateau early after the onset of the cognitive symptoms or even in the preclinical phase of the disease (Ingelsson et al. 2004; Serrano-Pozo et al. 2011) and not even the size of the plaques grows significantly with the progression of the disease (Hyman et al. 1993). However, it is possible that the amount of amyloid measured over the entire cortical mantle does increase during the clinical course of the disease as the distribution of amyloid deposits "spread" following the above stages. Preliminary data from longitudinal amyloid PET imaging studies in living patients have recently supported this possibility (Jack et al. 2009).

Cerebral Amyloid Angiopathy

Composition
The amyloid-β peptide not only deposits in the brain parenchyma in the form of amyloid plaques but also in the vessel walls in the form of cerebral amyloid angiopathy (CAA). Indeed, the more insoluble and aggregation-prone Aβ42 peptide tends to accumulate in the core of senile plaques, while the more soluble Aβ40 peptide is the major constituent of CAA, accumulating mainly in the interstitium between the smooth muscle cells of the tunica media. Although CAA can also appear in isolation (pure CAA), it is more common in the context of AD, with ≈80% of AD patients showing some degree, usually mild, of CAA at autopsy, antibodies. A morphological staging system has been implemented to describe the severity of CAA within a single vessel: grade 0 or absence of staining; grade 1 or congophilic rim around an otherwise normal-appearance vessel; grade 2 or complete replacement of the tunica media by congophilic material; grade 3 or cracking of ≥50% of the circumference of the vessel, giving a “vessel-within-vessel” or “double-barrel” appearance; and grade 4 or fibrinoid necrosis of the vessel wall, often accompanied by additional amyloid deposits in the surrounding neuropil (“dyshoric” changes) (Greenberg and Vonsattel 1997). In this severe stage, Prussian blue (Perl’s) staining is useful to show hemosiderin-laden macrophages in the parenchyma surrounding CAA-affected vessels, indicative of chronic microbleeds.

Morphological Characteristics
The same methods described for the examination of amyloid plaques are valid for CAA, that is Thioflavin-S or Congo red staining or immunohistochemical studies with anti-Aβ antibodies. A morphological staging system has been proposed to characterize the severity of CAA within a region of the cortex: 0 = no Thioflavin-S-stained leptomeningeal or cortical vessels; 1 = scattered positivity in either leptomeningeal or cortical vessels; 2 = strong circumferential positivity in at least some vessels either leptomeningeal or cortical; 3 = widespread circumferential staining in many leptomeningeal and cortical vessels, and 4 = presence of “dyshoric” perivascular amyloid deposits in addition to score 3. A global severity score can be obtained by averaging the scores from several regions (Olichney et al. 2000).

Clinicopathological Correlations
According to the Boston criteria, CAA should be suspected after one or multiple major symptomatic lobar hemorrhages in an elderly patient...
Knudsen et al. 2001). But in the context of AD, unless it becomes symptomatic because of this hemorrhagic complication, CAA is usually diagnosed at autopsy. However, three independent postmortem longitudinal studies have revealed that the otherwise apparently asymptomatic CAA can also be a synergistic contributor to cognitive decline in AD (MRC CFAS 2001; Pfeifer et al. 2002; Greenberg et al. 2004; Arvanitakis et al. 2011).

Granuovacuolar Degeneration and Hirano Bodies

Granulovacuolar degeneration (GVD) and Hirano bodies are two poorly understood lesions present in the cytoplasm of hippocampal pyramidal neurons of AD patients. Although they are increasingly observed with aging in cognitively intact elderly people, these two lesions are more severe and frequent in age-matched AD patients. (Ball 1978; Xu et al. 1992).

GVD consists of the accumulation of large double-membrane bodies. Their origin and significance are uncertain. Early immunohistochemical studies reported immunoreactivity of GVD bodies for cytoskeletal proteins including tubulin, neurofilament proteins and tau (Kahn et al. 1985; Price et al. 1986; Dickson et al. 1987; Bondareff et al. 1991; Mena et al. 1992; Ikegami et al. 1996). Because GVD bodies are also positive for some tau kinases, a role in tangle formation has been proposed (Ghoshal et al. 1999; Leroy et al. 2002; Kannanayakal et al. 2006). Other authors have postulated a role in the apoptotic cell death because of their immunoreactivity for activated caspase-3 (Selznic et al. 1999; Stadelmann et al. 1999; Su et al. 2002). More recent studies have suggested that these bodies might derive from the endoplasmic reticulum and represent the stress granules that feature the unfolded protein response, because they are positive for several stress kinases (Zhu et al. 2001; Lagalwar et al. 2007; Thakur et al. 2007; Hoozemans et al. 2009). Finally, based on their positivity for ubiquitin and autophagic markers, it has been proposed that these granules are late-stage autophagic vacuoles (Okamoto et al. 1991; Barrachina et al. 2006; Yamazaki et al. 2010; Funk et al. 2011).

Hirano bodies are eosinophilic rod-like cytoplasmic inclusions relatively common in the stratum lacunosum of the hippocampal CA1 region in the elderly. However, in AD patients the number of Hirano bodies is abnormally high and they are translocated to the neurons of the stratum pyramidale (Gibson and Tomlison 1977). Although the significance of Hirano bodies in AD is not completely understood, they are recognized by antibodies against tau, neurofilament proteins, actin, and other cytoskeletal proteins (Goldman 1983; Galloway et al. 1987a,b; Schmidt et al. 1989; Maciver and Harrison 1995; Rossiter et al. 2000). Other immunoreactivities associated with Hirano bodies are inducible nitric oxide synthase (Lee et al. 1999), advanced glycation endproducts (Münch et al. 1998), and the carboxy-terminal fragments of APP (Muñoz et al. 1993).

Glial Responses

Reactive astrocytes and activated microglial cells are commonly associated to dense-core amyloid plaques, indicating that amyloid-β is a major trigger of this glial response (Itagaki et al. 1989; Pike et al. 1995; Vehmas et al. 2003). However, we have recently observed a linear increase in reactive astrocytes and activated microglial cells through the entire disease course despite an early plateau in amyloid deposition in the temporal associative isocortex. Indeed, we found a highly significant positive correlation between both astrocytosis and microgliosis and NFT burden but not between both reactive glial cell types and amyloid burden, suggesting that glial responses are also related to neurofibrillary degeneration (Ingelsson et al. 2004; Serrano-Pozo et al. 2011).

Neuronal Loss

Neuronal loss is the main pathological substrate of cortical atrophy and, although usually evident in sections stained with hematoxylin and eosin, it can be more readily shown with a Nissl staining or a NeuN immunohistochemistry. Nissl staining (for example with cresyl...
violet) reveals the negatively charged ribosomal RNA present in the ribosomes of the rough endoplasmic reticulum (Nissl substance or granules), giving a dark blue appearance to the perinuclear region of neurons. By contrast, NeuN is a neuronal-specific nuclear antigen, although NeuN immunohistochemistry also stains the perinuclear region and some proximal processes of neurons.

The regional and laminar pattern of neuronal loss matches that of NFTs, but, importantly, within the same region neuronal loss exceeds the numbers of NFTs, so that it is a better correlate of cognitive deficits than the number of NFTs (Gómez-Isla et al. 1996, 1997). Indeed, quantitative stereology-based studies of neurons, iNFTs and eNFTs have concluded that iNFTs can last for up to two decades and that neurons bearing iNFTs might still be viable as evidenced by their positive Nissl staining (Busière et al. 2003; Hof et al. 2003). This dissociation between the extent of neuronal loss and that of NFTs suggests that there are at least two mechanisms of neuronal death in AD: one affecting tangle-bearing neurons, that will lead to the appearance of ghost extracellular tangles, and another affecting tangle-free neurons. Although the mechanisms of neuronal death in AD are beyond the scope of this article, it will be noted that postmortem studies on apoptosis have yielded controversial results, with some studies showing a widespread distribution of apoptotic markers (Troncoso et al. 1996; Su et al. 2001), while others have only reported a scattered distribution (Selnick et al. 1999; Woodhouse et al. 2006b).

**Synapse Loss**

Besides neuronal loss, synapse loss is another contributor to the cortical atrophy of the AD brain. Synapse loss in AD was shown with immunohistochemical studies using antibodies against pre- or postsynaptic proteins—typically the presynaptic protein synaptophysin—and with electron microscopy studies.

The spatiotemporal and laminar pattern of synapse loss matches that of neuron loss. Synaptic loss is not only caused by neuronal loss but can exceed the existing neuronal loss within a particular cortical area. This indicates that synapse loss predates neuronal loss and that the remaining neurons become less well connected to their synaptic partners than expected just by the number of viable neurons surviving in a particular circuit. Likely this is why synaptic density is the best correlate of cognitive decline in AD (DeKosky and Scheff 1990; Scheff et al. 1990, 1993, 2007; Terry et al. 1991; Masliah et al. 1994; Ingelsson et al. 2004). Interestingly, an inverse correlation has been observed between synaptic density and the size of remaining synapses as measured by the length of the postsynaptic density. This enlargement of remaining synapses has been interpreted as a compensatory response, rather than as selective loss of small synapses (DeKosky and Scheff 1990; Scheff et al. 1990; Scheff and Price 1993).

**CRITERIA FOR THE PATHOLOGICAL DIAGNOSIS OF ALZHEIMER DISEASE**

Of all pathological features described above, amyloid plaques and NFTs are the most characteristic of AD and, understandably, the criteria for the pathological diagnosis of AD rely on their amount and/or distribution.

The first pathological criteria for the diagnosis of AD were based on the highest density of total amyloid plaques (both diffuse and neuritic) in any cortical field, adjusted for age so that the older the patient at death, the greater the density required for diagnosis (Khachaturian 1985). The presence of NFTs was not required and diffuse plaques—relatively frequent in nondemented elderly people—had the same consideration as neuritic plaques. Although meritorious, these criteria were soon abandoned because, despite a very high sensitivity to diagnose AD dementia, they lacked sufficient specificity (Geddes et al. 1997). In 1991, the Consortium to Establish a Registry for Alzheimer Disease (CERAD) proposed more specific diagnostic criteria by emphasizing the importance of neuritic plaques over diffuse plaques (Mirra et al. 1991, 1997). CERAD criteria use a semiquantitative score of the density of neuritic plaques in the most severely affected region of
the isocortex (frontal, temporal, or parietal) and the patient’s age at death to obtain an age-related plaque score. This score is then integrated with clinical information regarding the presence or absence of dementia to establish one of three levels of certainty that dementia is explained by the AD pathological changes: possible, probable, and definite. A diagnosis of AD is made if the criteria for probable or definite AD are met. Although higher than that of Khachaturian criteria, the specificity of CERAD criteria proved to be still insufficient because they did not incorporate the scoring of the severity of NFTs (Geddes et al. 1997). By contrast, the use of Braak and Braak staging of NFTs alone—with the isocortical stages V and VI as criteria of definite AD—showed a high specificity at the expense of a low sensitivity (Geddes et al. 1997).

Current pathological criteria for AD were defined in 1997 by a workshop of the National Institute of Aging and the Reagan Institute. The NIA-RI consensus recommendations combine the CERAD semiquantitative score of neuritic plaques and the Braak and Braak staging of NFTs to distinguish three probabilistic diagnostic categories: (1) high likelihood, if there are frequent neuritic plaques (CERAD definite) and abundant isocortical NFTs (Braak stage V/VI); (2) intermediate likelihood, if there are moderate neuritic plaques (CERAD probable) and NFTs are restricted to limbic regions (Braak III/IV), and (3) low likelihood, if there are infrequent neuritic plaques (CERAD possible) and NFTs are restricted to the entorhinal cortex and/or hippocampus (Braak I/II). A diagnosis of AD is made when the criteria for intermediate or high likelihood of AD are met and the patient had a clinical history of dementia (NIA-RI Consensus 1997). Because experience has revealed infrequent cases with many AD pathological lesions but no or few cognitive symptoms (and vice versa) and these circumstances were not addressed by the NIA-RI consensus workgroup, these diagnostic criteria are currently under review.

Both CERAD and NIA-RI criteria also incorporated the assessment of other pathologies, particularly vascular and Lewy body diseases, already recognizing the high prevalence of mixed pathologies underlying dementia in elderly people, a circumstance well documented by more recent longitudinal community-based clinicopathological studies (MRC CFAS 2001; Schneider et al. 2007). Thus, in many practical instances, the CERAD criteria for “possible AD” and the NIA-RI criteria for “intermediate probability of AD” are not only based on a moderate amount and distribution of AD pathology but also on the coexistence of vascular or Lewy body pathology with sufficient severity to contribute to the patient’s dementia.

NEUROPATHOLOGY OF MILD COGNITIVE IMPAIRMENT AND EARLY ALZHEIMER DISEASE

Clinicopathological correlation studies have taught us that at the moment of the clinical diagnosis, patients with AD-type dementia often already have a Braak stage V or VI of neurofibrillary degeneration and a substantial and widespread synaptic and neuronal loss. To anticipate the clinical diagnosis of AD before the stage of full-blown dementia, a new clinical construct was needed. Petersen et al. proposed the concept of “mild cognitive impairment” (MCI) as a new diagnostic entity for the transition between normal aging and AD dementia. Patients with MCI have already some cognitive complaints that are detectable with the appropriate cognitive tests and represent a decline from a previous higher baseline level but that, unlike the definition of dementia, do not interfere with their activities of daily life. Importantly, MCI patients have an increased risk of developing dementia, which has been reported between 10% and 15% per year (Petersen et al. 1999, 2001; Petersen 2004).

Autopsy studies on MCI patients are scarce but they have reproducibly found a stage of AD pathology intermediate between cognitively intact subjects and demented patients, particularly regarding neurofibrillary degeneration, that is consistent with the idea of a transition phase between normal aging and definite AD (Jicha et al. 2006; Markesbery et al. 2006; Petersen et al. 2006; Schneider et al. 2009). Specifically, MCI patients usually have
a moderate number of neuritic plaques and a limbic stage of NFTs (Braak stage III or IV), fitting into the NIA-RI category of intermediate likelihood of AD (sufficient to cause dementia) and providing a pathological validation for this clinical construct. Along the same lines, patients with a Clinical Dementia Rating score of 0.5 (equivalent to MCI or very mild AD) have already a ≈30% of neuron loss in the entorhinal cortex compared to cognitively intact controls (CDR = 0), but still no evident neuronal loss in the superior temporal sulcus (Gómez-Isla et al. 1996, 1997). Moreover, electron microscopy studies have shown that MCI patients also have an intermediate number of synapses between nondemented controls and mild AD patients in the hippocampus, further indicating that many individuals with the clinical symptoms of MCI have early AD (Scheff et al. 2006, 2007). Of note, a paradoxical, presumably compensatory, up-regulation in the density of presynaptic glutamatergic boutons has been reported in the frontal cortex of MCI patients compared to nondemented controls and mild AD patients (Bell et al. 2007).

Although AD was the most common pathological diagnosis underlying MCI in the above case series, it should be noted that there was a high degree of pathological heterogeneity underlying the clinical diagnosis of MCI, with vascular disease, Lewy body disease, argyrophilic grain disease, and hippocampal sclerosis as major concurrent or alternative pathologies (Jicha et al. 2006; Petersen et al. 2006; Schneider et al. 2009). In addition, in the largest study a high proportion (up to 25%) of MCI patients had no pathology at autopsy (Schneider et al. 2009). Finally, no significant pathological differences have been observed between the amnestic and the nonamnestic subtypes of MCI nor in their pathological outcome after conversion to dementia (Jicha et al. 2006; Schneider et al. 2009).

ALZHEIMER NEUROPATHOLOGY IN “NORMAL AGING”

Longitudinal prospective clinicopathological studies in nondemented elderly people have revealed that up to 45% of nondemented elderly would meet the NIA-RI criteria for AD had they been demented, usually the intermediate likelihood category of these criteria, and rarely the high likelihood category (Schmitt et al. 2000; Knopman et al. 2003; Bennett et al. 2006; Price et al. 2009; Schneider et al. 2009). Moreover, the pattern of regional distribution of pathological changes in nondemented controls matches that of AD patients (Arriagada et al. 1992b). Thus, mounting evidence from clinicopathological studies support the view that AD is a continuous spectrum between asymptomatic lesions in cognitively normal elderly and dementia, with MCI as a transition phase between these two ends.

The apparent dissociation between AD pathology and cognitive status in some elderly people is remarkable because these so-called “high-pathology nondemented controls” or “individuals with asymptomatic AD” seem to be resilient to the neurotoxic effects of amyloid plaques and NFTs and to contradict the aforementioned positive correlation between NFT burden and cognitive decline. Understanding the biochemical and morphological substrates of this resilience to cognitive decline in the presence of abundant AD pathology might be crucial to discover new therapeutic targets for the disease. As expected from the highly significant clinicopathological correlations of synaptic and neuronal loss in AD, high-pathology controls have preserved synaptophysin levels compared to AD patients with a similar burden of plaques and NFTs (Lue et al. 1996), and they do not seem to have significant neuronal loss, not even in vulnerable regions such as the entorhinal cortex and the hippocampus (Price et al. 2001; West et al. 2004). Moreover, they have lower levels of neuroinflammatory markers than pathology-matched AD patients (Lue et al. 1996). This resistance to AD pathology has also been related to a nucleolar, nuclear, and cell body hypertrophy of the hippocampal and cortical neurons, suggestive of a compensatory metabolic activation to face the neurotoxic effects of AD lesions (Riudavets et al. 2007; Iacono et al. 2008). In keeping with these pathological reports, a MRI-neuropathological correlation study revealed larger brain and hippocampal...
volumes in high-pathology controls than in pathology-matched demented patients, further supporting the preservation of both neurons and synapses (Erten-Lyons et al. 2009).

OVERLAP OF AD WITH LEWY BODY DISEASE

Alzheimer disease and Parkinson’s disease (PD) are the leading causes of dementia and movement disorders in the aging population. It is estimated that over 10 million people live with these devastating neurological conditions in the United States. It is estimated that over 10 million people live with these devastating neurological conditions in the United States, and that this country alone will see a 50% annual increase of AD and PD by the year 2025 (Herbert et al. 2001).

PD and AD are two distinct clinicopathological entities. While in AD, abnormal accumulation of misfolded Aβ protein in the neocortex and limbic system is thought to be responsible for the neurodegenerative pathology (Selkoe 1990; Sisodia and Price 1995), intracellular accumulation of α-synuclein has been centrally implicated in the pathogenesis of PD (Spillantini et al. 1997; Hashimoto et al. 1998; Trojanowski and Lee 1998). In AD, Aβ protein accumulates in the intracellular (LaFerla et al. 1995; Skovronsky et al. 1998) and extracellular space, leading to the formation of plaques, whereas intracellular polymerization of phosphorylated cytoskeletal molecules such as tau results in the formation of neurofibrillary tangles (Greenberg and Davies 1990; Lee et al. 2001). In PD, intracellular accumulation of α-synuclein—an abundant synaptic terminal protein (Iwai et al. 1995)—results in the formation of characteristic inclusions called Lewy bodies (LBs) (Fig. 1F) (Spillantini et al. 1997; Wakabayashi et al. 1997; Takeda et al. 1998). The new consortium criteria for the classification of Lewy body diseases (LBD) recognizes two clinical entities, the first denominated dementia with LBs (DLB) and the second PD dementia (PDD) (McKeith et al. 1996; Aarsland et al. 2004; Burn 2006; McKeith 2006; Lippa et al. 2007). While in patients with DLB, the clinical presentation is of dementia followed by parkinsonism, in patients with PDD the initial signs are of parkinsonism followed by dementia (Litvan et al. 1998; Janvin et al. 2006; McKeith 2006). Interestingly, the brains of patients with DLB and PDD display very similar pathology, with the exception that recent studies have shown extensive deposition of Aβ and α-synuclein in the striatum and hippocampus in DLB compared to only α-synuclein in PDD cases (Duda et al. 2002; Jellinger and Atttems 2006). Because of the implications for the management and treatment of parkinsonism and dementia in patients with PD and DLB, loss of dopaminergic neurons in the midbrain (Dickson et al. 1994; Tsuboi and Dickson 2005) and cholinergic cells in the nucleus basalis of Meynert have been characterized in detail (Perry et al. 1978; Hansen et al. 1990). Although the severity of the neuronal loss within these subcortical regions might explain some of the neurological deficits in patients with PD and DLB, the neuronal populations responsible for the more complex cognitive and psychiatric alterations have not been completely characterized. Abnormal accumulation of α-synuclein in the CA2-3 region of the hippocampus (Harding and Halliday 2001; Bertrand et al. 2004), insula, amygdala and cingulate cortex has been shown to be an important neuropathological feature (Dickson et al. 1994; Spillantini et al. 1997; Trojanowski et al. 1998; Aarsland et al. 2004).

Remarkably, despite being initially considered distinct clinicopathological conditions, several studies have now confirmed that the clinical features and the pathology of AD and PD can overlap (McKeith 2000, 2006; Lippa et al. 2007). Approximately 25% of all patients with AD develop parkinsonism, and about 50% of all cases of PD develop AD-type dementia after 65 years of age (Hansen et al. 1990). Moreover, 70% of patients with sporadic AD display the formation of α-synuclein-positive LB-like inclusions in the amygdala and limbic structures (Lippa et al. 1998; Trojanowski et al. 1998; Hamilton 2000). Similarly, in patients with familial AD (FAD) and Down syndrome, LB-like pathology and parkinsonism have
been reported (Lippa et al. 1999). Last, as mentioned above, the single most important neuropathological finding that distinguishes PDD from DLB is the presence of Aβ deposits in the striatum (Duda et al. 2002) and in the hippocampus (Masliah et al. 1993a).

A number of studies provide extensive support for an interaction between pathogenic pathways in AD and LBD and argue against a coincidental concurrence of both disorders (i.e., merely because of their high prevalence in the elderly). FAD cases with presenilin mutations that present with significant LB pathology strongly support an interaction between Aβ and α-synuclein (Rosenberg 2005; Snider et al. 2005; Leverenz et al. 2006). Although plaques, tangles and LBs are useful neuropathological and diagnostic markers of these disorders, the initial injury that results in the cognitive and movement alterations is likely the damage of the synaptic terminals in selected circuitries (DeKosky and Scheff 1990; Masliah and Terry 1993; Masliah et al. 1994, 2001a, Klucken et al. 2003). Several lines of investigation support the notion that oligomeric forms of Aβ and α-synuclein, rather than the polymers and fibrils associated with plaques and LBs, accumulate in the neuronal membranes and lead to the characteristic synaptic pathology (Lambert et al. 1998; Conway et al. 2000; Lashuel et al. 2002; Haass and Selkoe 2007; Kramer and Schulz-Schaeffer 2007; Koffie et al. 2009; Scott et al. 2010). Some studies have shown that underlying interactions between α-synuclein and Aβ play a fundamental role in the pathogenesis of LBD (Lippa et al. 1998; Hashimoto et al. 2000; Masliah et al. 2001b, Pletnikova et al. 2005). Specifically, Aβ promotes the oligomerization and toxic conversion of α-synuclein (Masliah et al. 2001b; Mandal et al. 2006), Aβ exacerbates the deficits associated with α-synuclein accumulation, Aβ and α-synuclein colocalize in membrane and caveolar fractions, and Aβ stabilizes α-synuclein multimers that might form channel-like structures in the membrane (Tsigelny et al. 2007, 2008). Both lysosomal leakage (Nixon and Cataldo 2006) and oxidative stress (Smith et al. 1996) appear to be involved in the process of neurotoxicity and pathological interactions between Aβ and α-synuclein (Rockenstein et al. 2005).

Therefore, it is possible that the combined effects of α-synuclein and Aβ might lead to synaptic damage and selective degeneration of neurons in the neocortical, limbic, and subcortical regions. A more precise mapping of the neuronal populations affected in these regions is needed to understand the cellular basis for the characteristic cognitive dysfunction in PDD and DLB and to develop new treatments for these conditions.

CONCLUSIONS

Classical neuropathological lesions including senile amyloid plaques and neurofibrillary tangles define AD but they likely represent the “tip of the iceberg” of the pathological alterations that cause the cognitive decline associated with AD. Indeed, the development of new biomarkers and imaging tools has made evident that these neuropathological stigmata of AD begin to accumulate a decade or more prior to a clinical diagnosis of dementia. Synaptic loss, plasticity changes, neuronal loss, and the presence of soluble microscopic oligomeric forms of Aβ and even of tau, likely contribute to the progressive neural system failure that occurs over decades. An understanding of this natural history of the disease is critical to design primary or secondary prevention strategies to halt the disease progression before the damage to the neural system becomes irreversible.

ACKNOWLEDGMENTS

This work was funded by the National Institutes of Health grants AG5131, AG18840, AG22074, NS057096, and AG10435 (to E.M.), and P50AG05134 and AG08487 (to B.T.H. and M.P.F.). A.S.P. was supported with a Research Fellowship from Fundación Alfonso Martín Escudero (Madrid, Spain).

REFERENCES

A. Serrano-Pozo et al.


Bondareff W, Wischik CM, Novak M, Roth M. 1991. Seques-

tation of tau by granulovacuolar degeneration in Alz-


Braak H, Braak E. 1991. Neuropathological staging of Alz-


Coleman MP, Perry VH. 2002. Axon pathology in neurologi-


Crews L, Masliah E. 2010. Molecular mechanisms of neuro-


DeKosky ST, Scheff SW, Styren SD. 1996. Structural corre-

lates of cognition in dementia: Quantification and assess-


Neuropathological Alterations in Alzheimer Disease


A. Serrano-Pozo et al.


Neuropathological Alterations in Alzheimer Disease


A. Serrano-Pozo et al.


Neuropathological Alterations in Alzheimer Disease


A. Serrano-Pozo et al.


Neuropathological Alterations in Alzheimer Disease

Alberto Serrano-Pozo, Matthew P. Frosch, Eliezer Masliah and Bradley T. Hyman

*Cold Spring Harb Perspect Med* 2011; doi: 10.1101/cshperspect.a006189

<table>
<thead>
<tr>
<th>Subject Collection</th>
<th>The Biology of Alzheimer Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animal Models of Alzheimer Disease</td>
<td>Alzheimer Disease in 2020</td>
</tr>
<tr>
<td>Frank M. LaFerla and Kim N. Green</td>
<td>David M. Holtzman, Eckhard Mandelkow and Dennis J. Selkoe</td>
</tr>
<tr>
<td>Neurovascular Dysfunction and Faulty Amyloid β -Peptide Clearance in Alzheimer Disease</td>
<td>The Genetics of Alzheimer Disease</td>
</tr>
<tr>
<td>Abhay P. Sagare, Robert D. Bell and Berislav V. Zlokovic</td>
<td>Rudolph E. Tanzi</td>
</tr>
<tr>
<td>Treatment Strategies Targeting Amyloid β-Protein</td>
<td>Fluid Biomarkers in Alzheimer Disease</td>
</tr>
<tr>
<td>Dale Schenk, Guriqbal S. Basi and Menelas N. Pangalos</td>
<td>Kaj Blennow, Henrik Zetterberg and Anne M. Fagan</td>
</tr>
<tr>
<td>The Ubiquitin–Proteasome System and the Autophagic–Lysosomal System in Alzheimer Disease</td>
<td>Epidemiology of Alzheimer Disease</td>
</tr>
<tr>
<td>Yasuo Ihara, Maho Morishima-Kawashima and Ralph Nixon</td>
<td>Richard Mayeux and Yaakov Stern</td>
</tr>
<tr>
<td>Neurotoxicity of Amyloid β-Protein: Synaptic and Network Dysfunction</td>
<td>Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration</td>
</tr>
<tr>
<td>Lennart Mucke and Dennis J. Selkoe</td>
<td>Eva-Maria Mandelkow and Eckhard Mandelkow</td>
</tr>
<tr>
<td>Proteolytic Degradation of Amyloid β-Protein</td>
<td>Biochemistry of Amyloid β-Protein and Amyloid Deposits in Alzheimer Disease</td>
</tr>
<tr>
<td>Takaomi Saido and Malcolm A. Leissring</td>
<td>Colin L. Masters and Dennis J. Selkoe</td>
</tr>
<tr>
<td>Brain Imaging in Alzheimer Disease</td>
<td>The Neuropsychological Profile of Alzheimer Disease</td>
</tr>
<tr>
<td>Keith A. Johnson, Nick C. Fox, Reisa A. Sperling, et al.</td>
<td>Sandra Weintraub, Alissa H. Wicklund and David P. Salmon</td>
</tr>
<tr>
<td>Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease</td>
<td>Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease</td>
</tr>
<tr>
<td>Paul S. Aisen, Jeffrey Cummings and Lon S. Schneider</td>
<td>David M. Holtzman, Joachim Herz and Guojun Bu</td>
</tr>
</tbody>
</table>

For additional articles in this collection, see [http://perspectivesinmedicine.cshlp.org/cgi/collection/](http://perspectivesinmedicine.cshlp.org/cgi/collection/)